Multiple compounds that ameliorate NAFL and/or NASH, including salidroside, salvianolic acid A, quercetin plus allopurinol, and retinoic acid, function through inhibition of hepatic Txnip expression 26-29, suggesting a pathogenic role of TXNIP in NASH development. Here, TXNIP is linked to non-alcoholic fatty liver.